Usage of compromised lung volume in monitoring steroid therapy on severe COVID-19

Respiratory Research

Table 2 Quantitative chest CT parameters (%) during the follow-up period

Quantitative chest CT parameters (%)	Stage 1			Stage 2			Stage 3
Quantitative chest CT parameters (%)	Entire cohort (n = 72)	Steroid group (n = 31)	Standard care group (n = 41)	Entire cohort (n = 62)	Steroid group (n = 27)	Standard care group (n = 35)	Entire cohort (n = 65)	Steroid group (n = 29)	Standard care group (n = 36)
%CL	23.90 [19.83,36.11]	36.45 [25.12,48.53]*	22.29 [18.81,24.36]	22.38 [19.89,29.54]	28.35 [22.47,40.52]*	20.57 [18.63,24.13]	21.92 [18.88,31.81]	24.95 [20.90,34.29]*	19.30 [17.91,26.73]
%NNL	18.02 [15.91,21.35]	20.22 [17.72,24.37]*	17.05 [15.71,18.53]	17.26 [16.01,20.15]	18.93 [17.19,23.28]*	16.52 [15.60,18.03]	17.03 [15.62,20.75]	17.35 [16.35,22.23]	16.20 [15.50,20.13]
%PAL	5.92 [3.81,13.59]	13.73 [7.06,20.00]*	4.18 [2.97,5.97]	5.10 [3.47,8.74]	8.98 [5.88,17.93]*	3.63 [2.78,5.67]	4.67 [2.87,9.79]	7.05 [4.57,14.42]*	3.24 [2.31,6.38]
%NAL	59.23 [50.79,67.26]	57.20 [46.68,66.59]	61.69 [53.69,68.51]	61.31 [55.10,70.01]	62.25 [53.28,70.09]	60.78 [55.65,69.75]	58.72 [51.95,67.24]	61.96 [54.71,71.88]*	57.59 [49.00,62.34]
%HI	7.62 [2.12,19.40]	2.39 [1.40,7.72]*	14.11 [6.90,23.29]	7.93 [3.44,19.27]	4.65 [2.13,7.23]*	17.58 [7.17,25.27]	10.57 [3.50,22.23]	5.87 [2.57,11.79]*	20.12 [5.72,30.17]

Quantitative chest CT parameters (%)	Stage 4			Stage 5
Quantitative chest CT parameters (%)	Entire cohort (n = 56)	Steroid group (n = 29)	Standard care group (n = 27)	Entire cohort (n = 45)	Steroid group (n = 25)	Standard care group (n = 20)
%CL	21.44 [18.18,27.84]	23.91 [19.80,29.57]*	19.61 [17.73,26.50]	22.49 [18.44,30.80]	22.49 [18.56,30.80]	22.65 [17.85,30.37]
%NNL	16.72 [15.52,19.40]	16.56 [15.78,20.92]	16.88 [15.28,18.94]	17.10 [15.35,22.47]	17.10 [15.40,22.53]	17.00 [15.31,22.08]
%PAL	4.28 [2.63,8.49]	4.92 [3.83,10.69]*	2.97 [2.20,7.46]	5.41 [2.66,8.15]	5.41 [2.95,8.38]	5.16 [2.37,7.12]
%NAL	58.46 [53.41,68.98]	62.01 [55.39,70.18]*	55.64 [45.57,62.51]	60.32 [53.37,66.56]	61.72 [56.39,68.62]*	56.25 [44.75,62.06]
%HI	12.81 [5.64,25.04]	9.42 [4.46,14.46]*	21.78 [8.42,34.32]	13.21 [3.45,23.48]	6.38 [2.22,17.04] **	19.90 [4.28,33.03]

Data are expressed as the median with interquartile range in square brackets for non-normally distributed data. The Kruskal–Wallis analysis of variance was used for non-normally distributed data comparison
%CL, percentage of compromised lung volume, considered as the sum of %PAL and %NNL; %NNL, percentage of nonaerated lung volume; %PAL, percentage of poorly aerated lung volume; %NAL, percentage of normally aerated lung volume; %HI, percentage of hyperinflated lung volume.* denotes P < 0.05 between two groups at each stage

ISSN: 1465-993X